Literature DB >> 18057303

The first biosimilar epoetin: but how similar is it?

Huub Schellekens1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18057303     DOI： 10.2215/CJN.04251007

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  10 in total

1.  EU's new pharmacovigilance legislation: considerations for biosimilars.

Authors:  Begoña Calvo; Leyre Zuñiga
Journal:  Drug Saf       Date:  2014-01       Impact factor: 5.606

2.  Biosimilars 2.0: guiding principles for a global "patients first" standard.

Authors:  Joseph Miletich; Geoffrey Eich; Gustavo Grampp; Barbara Mounho
Journal:  MAbs       Date:  2011-05-01       Impact factor: 5.857

Review 3.  Emerging erythropoiesis-stimulating agents.

Authors:  Robert N Foley
Journal:  Nat Rev Nephrol       Date:  2010-02-23       Impact factor: 28.314

Review 4.  Generic Substitution of Orphan Drugs for the Treatment of Rare Diseases: Exploring the Potential Challenges.

Authors:  Antonello Di Paolo; Elena Arrigoni
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

Review 5.  The emergence of biosimilar insulin preparations--a cause for concern?

Authors:  David R Owens; Wolfgang Landgraf; Andrea Schmidt; Reinhard G Bretzel; Martin K Kuhlmann
Journal:  Diabetes Technol Ther       Date:  2012-10-09       Impact factor: 6.118

Review 6.  Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease.

Authors:  Walter H Hörl
Journal:  Drugs       Date:  2013-02       Impact factor: 9.546

Review 7.  Biosimilar agents in oncology/haematology: from approval to practice.

Authors:  Dietger Niederwieser; Stephan Schmitz
Journal:  Eur J Haematol       Date:  2011-01-25       Impact factor: 2.997

Review 8.  Clinical trials for authorized biosimilars in the European Union: a systematic review.

Authors:  Johanna Mielke; Bernd Jilma; Franz Koenig; Byron Jones
Journal:  Br J Clin Pharmacol       Date:  2016-09-05       Impact factor: 4.335

9.  Biosimilar therapeutics-what do we need to consider?

Authors:  Huub Schellekens
Journal:  NDT Plus       Date:  2009-01

Review 10.  Biosimilars: potential implications for clinicians.

Authors:  Misty G Eleryan; Sophia Akhiyat; Monica Rengifo-Pardo; Alison Ehrlich
Journal:  Clin Cosmet Investig Dermatol       Date:  2016-06-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.